Thelansis’s "NGLY1 Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential NGLY1 Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
NGLY1 deficiency is a devastating, ultra-rare autosomal recessive congenital disorder of deglycosylation (CDDG) caused by biallelic loss-of-function mutations in the NGLY1 gene. This gene encodes N-glycanase 1, a critical cytosolic enzyme responsible for cleaving N-linked glycans from misfolded glycoproteins prior to their destruction by the proteasome. The fundamental absence of this enzyme critically cripples the endoplasmic reticulum-associated degradation (ERAD) pathway, driving the toxic intracellular accumulation of misfolded proteins and elevating the defining diagnostic biomarker, GlcNAc-Asn (GNA). Clinically, the disease manifests with a highly distinct tetrad of severe global developmental delay, a progressive hyperkinetic movement disorder, transient hepatic transaminase elevations, and the hallmark ocular symptom of (hypo)alacrima (reduced or absent tears). While historical management was strictly palliative—relying entirely on supportive physical and occupational therapies alongside aggressive, symptom-directed care—the therapeutic landscape is currently undergoing a monumental transformation. As of March 2026, the clinical focus has shifted entirely toward definitive genetic correction, spearheaded by the recent FDA Regenerative Medicine Advanced Therapy (RMAT) designation of GS-100. This groundbreaking, investigational AAV9-mediated gene replacement therapy, administered directly via intracerebroventricular (ICV) injection, targets the absolute root cause of the condition and represents the first viable pipeline strategy to halt neurologic progression and dramatically alter the natural history of this profound disorder.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest NGLY1 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the NGLY1 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.